Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

Researchers at the Children's Cancer Institute and UNSW Sydney have tested a new way of treating childhood brain cancer by ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Modeyso for patients with H3 K27M-mutant diffuse midline glioma. The therapy showed an overall ...

A team of Australian researchers has tested a new way of treating childhood brain cancer by combining two medicines in lab ...

Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based immunotherapy ...

DUBLIN, Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso ™ ...

Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors found in the pontine region of the brainstem. Due to their high intratumoral genetic and cellular heterogeneity and ...

DUBLIN, Sept. 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical ...

These tumors are less likely to spread to surrounding tissues than higher-grade tumors, so they often have better outcomes. In the past, pediatric gliomas were classified into low-grade and high-grade ...